

**Supplemental Digital Content 8.** EQ-5D-5L Health State Utility and VAS at Baseline and Week 144

	DTG + 3TC		DTG + TDF/FTC		Adjusted difference <sup>a</sup> (95% CI)	P value
	Baseline, mean (SD)	Week 144, mean (SD)	Baseline, mean (SD)	Week 144, mean (SD)		
EQ-5D-5L	0.95 (0.08)	0.97 (0.08)	0.94 (0.10)	0.96 (0.09)	0.004 (-0.003, 0.012)	0.273
VAS	86.5 (12.1)	91.0 (9.7)	85.1 (13.4)	89.4 (10.7)	1.2 (0.3, 2.2)	0.012

DTG, dolutegravir; EQ-5D-5L, EuroQol-5 Dimensions-5 Levels; FTC, emtricitabine; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate; VAS, visual analog scale.

<sup>a</sup>Statistical analysis of mean change from baseline using a mixed-effect repeated-measures model adjusting for study, treatment, baseline plasma HIV-1 RNA, baseline CD4+ cell count, and baseline score, treatment-by-visit interaction, and baseline score-by-visit interaction as factors and covariate, with visit as the repeated factor.